Impact Biomedical (IBO) Cash from Investing Activities (2022 - 2026)
Impact Biomedical (IBO) posted Cash from Investing Activities of -$1000.0 for Q1 2026, down 200.0% on a QoQ basis from $1000.0 in Q4 2025, and down 200.0% year-over-year from $1000.0 in Q1 2025.
Impact Biomedical (IBO) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Impact Biomedical's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$1000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 200.0% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1000.0 (down 66.67% YoY) and the FY2025 annual result came in at $3000.0, up 50.0% from the prior year.
- Cash from Investing Activities was -$1000.0 for Q1 2026 at Impact Biomedical, down from $1000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1000.0 in Q4 2023 and bottomed at -$275000.0 in Q4 2022.
- A 5-year average of -$26181.8 and a median of -$1000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities surged 200.0% — and 2026, when it plunged 200.0%.
- Impact Biomedical's Cash from Investing Activities stood at -$275000.0 in 2022, then jumped by 100.36% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then changed by 0.0% to $1000.0 in 2025, then plunged by 200.0% to -$1000.0 in 2026.
- Business Quant data shows IBO's Cash from Investing Activities at -$1000.0 in Q1 2026, $1000.0 in Q4 2025, and $1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Impact Biomedical | 46.36 Mn | 46.34 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -275,000.00 |
| Dec 31, 2022 | -275,000.00 |